# A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

> **NCT06906562** · PHASE2 · RECRUITING · sponsor: **Sameek Roychowdhury** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Pancreatic Carcinoma
- Metastatic Pancreatic Carcinoma
- Stage II Pancreatic Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8

## Interventions

- **DRUG:** Pemigatinib
- **PROCEDURE:** Computed Tomography (CT)
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Optical Coherence Tomography
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** Ophthalmoscopy

## Key facts

- **NCT ID:** NCT06906562
- **Lead sponsor:** Sameek Roychowdhury
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-26
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06906562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06906562, "A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06906562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*